<DOC>
	<DOCNO>NCT00055445</DOCNO>
	<brief_summary>This study measure safety tolerability three different dos IdB 1016 patient hepatitis C disease respond poor candidate interferon-based therapy . NOTE : THE STUDY WILL ONLY RECRUIT STUDY PARTICIPANTS AT UNIVERSITY OF WASHINGTON MEDICAL CENTER IN SEATTLE</brief_summary>
	<brief_title>IdB 1016 Treatment Hepatitis C Disease</brief_title>
	<detailed_description>Results two open label four randomize placebo-controlled study patient liver disease diverse etiology suggest IdB 1016 ( oral silybin-phosphatidylcholine phytosome ) well tolerate significantly improve serum liver enzyme level . However , IdB 1016 dose study range 314 mg bid 314 mg tid , Phase I dose well tolerate healthy volunteer . None study test safety efficacy IdB 1016 strictly patient chronic hepatitis C disease measure post-treatment histologic change . This study open label , randomize , dose-finding study . There three arm correspond three different IdB 1016 dos : 314 mg , 624 mg , 942 mg tid . Each arm 15 patient diagnose chronic hepatitis C stratify five patient fibrosis stage II ( periportal fibrosis ) , five patient fibrosis stage III ( bridge fibrosis ) , five patient fibrosis stage IV ( compensate cirrhosis ) . The treatment duration 12 week . Patients follow additional 4 week treatment cessation ass residual effect measure parameter . Patients clinic visit Day -21 ( screen ) , Day 1 ( treatment initiation ) , Day 29 , Day 57 , Day 85 ( end treatment ) , Day 113 ( follow-up washout ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<criteria>HCV infection accord ELISA2 Detectable HCV RNA PCR measure within previous 6 month Poor responder , inadequate candidate , unwilling use interferonbased therapy Serum ALT &gt; = 1.3 time normal Persistently elevate serum ALT level accord two measure previous 12 month Evidence stage II ( periportal fibrosis ) , III ( bridge fibrosis ) , IV ( compensate cirrhosis ) BattsLudwig score system accord liver biopsy perform last 2 ( stage II III patient ) 5 ( stage IV patient ) year . Patients clinical sign compensate cirrhosis ( portal hypertension , nonbleeding varix ) require biopsy . Able willing follow protocol direction duration study Able willing maintain consistent lifestyle routine ( e.g. , diet , exercise , medication , dietary supplement ) sleep schedule duration study Able willing stop take dietary supplement outside study protocol duration study Able willing practice two method contraception study period , include 4 week followup . This apply woman childbearing potential men whose sexual partner childbearing potential . Pregnant breastfeed Liver synthetic dysfunction ( albumin &lt; 3.2 g/dL , total bilirubin &gt; 3.0 mg/dL , prothrombin time &gt; 1.5 second prolong ) History ascites , variceal bleeding , encephalopathy , jaundice , extrahepatic biliary obstruction History uncontrolled diabetes mellitus Known concomitant acute chronic viral liver infection ( e.g. , hepatitis A , hepatitis B , EpsteinBarr , cytomegalovirus ) Concomitant autoimmune inflammatory disease ( e.g. , rheumatoid arthritis , lupus ) Other type concomitant liver disease HIV1 coinfection Chronic use hepatotoxic drug ( e.g. , acetaminophen ) Interferonbased therapy past 6 month Alcohol consumption within 3 month prior entry . Patients history alcohol abuse least 2 year recovery . Use recreational oral IV drug . Patients history drug addiction least 2 year recovery . History untreated malignancy Remission previous malignant neoplasm &lt; = 6 month History significant renal , endocrine , cardiac , pulmonary disease Use supplement contain compound derive milk thistle Proven allergy milk thistle derive compound Subjects take warfarin coumadin due silybin 's potential interaction cytochrome CYP 29C Any condition concomitant medication supplement could hinder outcome study safety patient determine principal investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Complementary Therapies</keyword>
	<keyword>IdB 1016</keyword>
	<keyword>Silybin</keyword>
	<keyword>Antioxidant</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Phosphatidylcholine</keyword>
</DOC>